icon-folder.gif   Conference Reports for NATAP  
 
 

16thEuro

Back grey_arrow_rt.gif
 
 
 
Abacavir Hypersensitivity Reaction Reporting Rates in a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure
 
 
  Reported by Jules Levin
EACS - 16TH EUROPEAN AIDS CONFERENCE - MILAN, ITALY Oct 23-25
 
Rimgaile Urbaityte,2James Oyee,2Charlotte Lane,2Vani Vannappagari,3Judy Hopking,2Lindsay Carter,3Gary Pakes,3Mark Shaefer3 1ViiV Healthcare, London, UK; 2GlaxoSmithKline, London, UK;3ViiV Healthcare, Research Triangle Park, NC, USA

1103171

1103172

1103173

References: 1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-1614. 2. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579. 3. Cutrell A, Hernandez J, Fleming J, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171-2172.